Fisher Asset Management LLC Lowers Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Fisher Asset Management LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 8.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,782,489 shares of the biotechnology company’s stock after selling 269,648 shares during the quarter. Fisher Asset Management LLC owned 1.33% of BioCryst Pharmaceuticals worth $24,931,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Headlands Technologies LLC purchased a new stake in shares of BioCryst Pharmaceuticals in the 1st quarter valued at $32,000. New Age Alpha Advisors LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $62,000. Family Legacy Financial Solutions LLC acquired a new position in BioCryst Pharmaceuticals in the 2nd quarter valued at about $72,000. Allianz Asset Management GmbH increased its stake in BioCryst Pharmaceuticals by 9.6% during the first quarter. Allianz Asset Management GmbH now owns 13,700 shares of the biotechnology company’s stock worth $103,000 after purchasing an additional 1,200 shares during the period. Finally, Inceptionr LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the second quarter worth about $107,000. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on BCRX. Barclays dropped their price objective on shares of BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Needham & Company LLC dropped their price target on shares of BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th. Zacks Research cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Cantor Fitzgerald lifted their target price on BioCryst Pharmaceuticals from $24.00 to $26.00 and gave the company an “overweight” rating in a report on Wednesday, October 15th. Finally, TD Cowen initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $19.33.

BioCryst Pharmaceuticals Trading Up 0.4%

BCRX stock opened at $7.16 on Wednesday. The stock has a market cap of $1.51 billion, a P/E ratio of -143.20 and a beta of 0.91. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $11.31. The company’s 50 day moving average is $7.12 and its two-hundred day moving average is $8.38.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 3rd. The biotechnology company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). BioCryst Pharmaceuticals had a negative net margin of 1.46% and a negative return on equity of 4.24%. The company had revenue of $159.40 million during the quarter, compared to analysts’ expectations of $162.91 million. During the same period last year, the business earned ($0.07) earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.